NRx Pharma's Preservative-Free Ketamine Nears FDA Approval with Minor Labeling Feedback
NRXP sits 41% above its 52-week low of $1.58 on light trading volume (0.3× avg).
Summary
NRx Pharmaceuticals announced a significant regulatory milestone, receiving positive feedback from the FDA's Office of Generic Drugs regarding its preservative-free ketamine application. The FDA's comments were limited to minor formatting changes for the proposed label, indicating a smooth path forward. The company anticipates submitting the final label this month, with full ANDA approval expected in Summer 2026. This development is crucial for NRx, especially given its recent 10-K filing which included a 'going concern' warning and substantial share dilution. The FDA has identified ketamine as a 'highly strategic product' due to US supply shortages, and NRx's US-manufactured product could significantly address this need, potentially providing a material revenue stream. Traders should monitor the final label submission and the anticipated Summer 2026 approval, as well as progress on the related NDA for intravenous ketamine.
At the time of this announcement, NRXP was trading at $2.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $72.7M. The 52-week trading range was $1.58 to $3.84. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.